ClinicalTrials.gg
RecruitingNCT05229341Updated Nov 5, 2026

Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules

An interventional study of Diagnostic Procedure and Electronic Health Record Review in Thyroid Gland Carcinoma, sponsored by City of Hope Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by City of Hope Medical Center · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Dec 2021; still recruiting 4 years 10 months later.
Updated Nov 5, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,450
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 283 studies in Thyroid Neoplasms with a site in United States — 53 open to participants now, 88 under way, 3 of them phase 3. Thyroid Neoplasms · United States.

Planned enrollment
2nd of 231
1,450 · median 35
Started
2021
with 15 others
No phase
50 of 283
13 open now
Primary completion
2027-01
later than 28 of 82 live
Registered
238th of 283
by date

Among the 283 studies in Thyroid Neoplasms with a site in United States, this one is the 2nd largest by planned enrollment of the 231 interventional ones that give a count, is one of 16 that started in 2021, is one of 50 with no phase, reaches primary completion later than 28 of the 82 other live ones, and was the 238th registered.

Thyroid Neoplasms

785 studies on the registry are indexed under Thyroid Neoplasms; 203 are open to participants now.

Browse Thyroid Neoplasms studies →

Open to participants now

53 of the 283 studies in Thyroid Neoplasms with a site in United States are open now. Recruiting first, the newest first:

48 more — sign in →

All 53 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 151 Thyroid Neoplasms studies recruiting now, 95 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 36 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Thyroid Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This clinical trial evaluates deoxyribonucleic acid (DNA) methylation signatures in diagnosing and managing thyroid nodules. The purpose of this research is to develop a new test for thyroid cancer. This test will use needle biopsies (small collections of tissue with a needle) from the thyroid to determine whether the participant has a malignant (cancer) or benign (not showing cancer) thyroid tumor. The information learned from this trial may help develop a more accurate test so that patients do not have unnecessary surgeries for nodules that are thought to be suspicious but are actually benign.

Read the detailed description

PRIMARY OBJECTIVE:

I. To evaluate the effect of Diagnostic DNA Methylation Signatures (DDMS-2) results (positive predictive value [PPV], negative predictive value [NPV], sensitivity and specificity) on physician decision-making for clinical management of 800 indeterminate thyroid nodules.

SECONDARY OBJECTIVES:

I. To determine sensitivity and specificity, PPV, NPV of DDMS-2 with 1450 needle biopsies including 800 needle biopsies with indeterminate cytopathology.

II. Compare the diagnostic accuracy between DDMS-2 and two currently used diagnostic approaches based on genetic alterations and gene expression within the same prospective cohort of 800 indeterminate needle biopsies.

OUTLINE:

Patients undergo needle biopsy for collection of tissue samples. Tissue samples are analyzed using DDMS-2. Patients' medical records are also reviewed.

03

Conditions studied

  • Thyroid Gland Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients without impaired decision-making capacity and who are undergoing needle for thyroid nodule diagnosis
  • Over the age of 18
  • Any gender, race and ethnicity
  • Patients must provide prior to use of their tissues and clinical data

Exclusion criteria

Exclusion Criteria:

  • Children are excluded from the study, since the biology of children thyroid nodules is different from adults
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,450 participants (estimated)

Study arms

  • Experimental
    Diagnostic (needle biopsy, DDMS-2)

    Patients undergo needle biopsy for collection of tissue samples. Tissue samples are analyzed using DDMS-2. Patients' medical records are also reviewed.

    Procedure: Diagnostic Procedure · Other: Electronic Health Record Review · Procedure: Needle Biopsy

Interventions

  • ProcedureDiagnostic Procedure

    Analysis via DDMS-2

    Also known as: Diagnostic Method, Diagnostic Technique, Diagnostic Test

  • OtherElectronic Health Record Review

    Review of medical records

  • ProcedureNeedle Biopsy

    Undergo needle biopsy

    Also known as: Aspiration Biopsy, Puncture Biopsy

06

What researchers measure

Primary outcomes

  1. Sensitivity of Diagnostic Deoxyribonucleic Acid (DNA) Methylation Signatures (DDMS-2)

    The sensitivity of DDMS-2 will be estimated by taking the ratio of the number of true thyroid cancer specimens diagnosed as cancer by DDMS and the total number of thyroid cancer specimens. Will also determine the 95% confidence intervals.

    Time frame: Up to 5 years

  2. Specificity of DDMS-2

    The specificity will be estimated by taking the ratio of the number of true benign nodules diagnosed as benign by DDMS and the total number of true benign thyroid nodules. Will also determine the 95% confidence intervals.

    Time frame: Up to 5 years

  3. Positive predictive value (PPV) of DDMS-2

    PPV (number of true thyroid cancer specimens by DDMS / number of thyroid cancers diagnosis by DDMS) will be calculated. Will also determine the 95% confidence intervals.

    Time frame: Up to 5 years

  4. Negative predictive value (NPV) of DDMS-2

    NPV (number of true benign nodules diagnosed by DDMS/number of benign diagnosis by DDMS) will be calculated. Will also determine the 95% confidence intervals.

    Time frame: Up to 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2021 (actual). Primary completion is estimated for Jan 2027, 60 months after the start.

Of 126 non-industry interventional studies with no phase under Thyroid Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 78. This study's planned 60 months is above that.

Counting every sponsor, half of 127 studies reached it within 46 months; a quarter within 14 and three quarters within 78.

Start moved once since we started tracking on Sep 25, 2026: Oct 2021 → Dec 2021, on Oct 16, 2026.

Primary completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jan 2027, on Nov 5, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jan 2027, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2022
First posted
Feb 8, 2022
StartActual
Dec 23, 2021was Oct 2021
Primary completionEst.
Jan 21, 2027was Oct 2026
CompletionEst.
Jan 21, 2027was Oct 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 22, 2021→Dec 23, 2021
Oct 16, 2026
Primary completion
Oct 22, 2026→Jan 21, 2027
Nov 5, 2026
Study completion
Oct 22, 2026→Jan 21, 2027
Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    Primary completion Oct 22, 2026→Jan 21, 2027
    Study completion Oct 22, 2026→Jan 21, 2027
    + 1 other change: verification date
  2. Oct 16, 2026
    Start date Oct 22, 2021→Dec 23, 2021
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05229341
Responsible party
Sponsor
First posted
Feb 8, 2022
Start date
Dec 23, 2021
Primary completion
Jan 21, 2027 (estimated)
Completion
Jan 21, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

John H Yim
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion